Camden National Bank Sells 2,715 Shares of Elevance Health, Inc. $ELV

Camden National Bank lessened its position in shares of Elevance Health, Inc. (NYSE:ELV) by 21.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 10,106 shares of the company’s stock after selling 2,715 shares during the quarter. Camden National Bank’s holdings in Elevance Health were worth $3,265,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Norges Bank acquired a new stake in Elevance Health during the second quarter worth $1,148,379,000. Sanders Capital LLC boosted its position in shares of Elevance Health by 24.7% during the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock valued at $2,265,773,000 after acquiring an additional 1,152,440 shares in the last quarter. Beutel Goodman & Co Ltd. bought a new stake in Elevance Health in the second quarter valued at about $293,141,000. Vanguard Group Inc. raised its position in Elevance Health by 3.2% in the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock worth $8,890,419,000 after purchasing an additional 704,790 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Elevance Health by 30.7% during the second quarter. The Manufacturers Life Insurance Company now owns 2,076,668 shares of the company’s stock worth $807,741,000 after purchasing an additional 487,579 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Stock Up 3.1%

Shares of ELV opened at $346.49 on Friday. The firm has a market capitalization of $76.47 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 1.87 and a beta of 0.50. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. The business’s fifty day moving average price is $352.22 and its two-hundred day moving average price is $331.73.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. Elevance Health’s payout ratio is 27.23%.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ELV shares. Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Sanford C. Bernstein lowered their price target on Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. UBS Group set a $400.00 price objective on Elevance Health in a research note on Thursday, January 29th. Wells Fargo & Company reduced their target price on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Finally, Mizuho set a $413.00 price target on shares of Elevance Health in a research report on Friday, January 9th. Twelve analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.